losigamone（Ac－33）是一种新型强效抗癫痫药。该药与其他原型药不同，它对GABA受体、苯二氮革受体及印防己毒素受体结合没有抑制作用。大鼠胞切片实验显示，其药效学与苯受英相当，比丙戊酸强。该药口服吸收好，现处于临床D期开发过程中、本文报道了4个独立的临床1期对52例健 Losigamone (Ac-33) is a new potent antiepileptic drug. This drug, unlike other prototypes, has no inhibitory effect on GABA receptor, benzodiazepine receptor and picrronin receptor binding. Cell biopsy experiments in rats showed that its pharmacodynamics was comparable to that of benzene in England and stronger than valproic acid. The drug is well absorbed orally and is now in the process of clinical D phase development. This article reports the results of four independent clinical phase 1 trials of 52 cases of healthy